Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
This cross‐sectional study aims to compare the effectiveness of Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) in assessing HER2 amplification in breast carcinoma, which is pivotal for treatment strategy and prognosis. The study encompassed 200 patients diagnosed with breast carcinoma. HER2 status was initially assessed using IHC. Cases with equivocal or positive IHC results were further evaluated using FISH to confirm HER2 gene amplification. Statistical analysis was conducted to determine the concordance and discordance between the two methods. The results demonstrated a certain percentage of cases showing HER2 amplification. Concordance rates between IHC and FISH were high, with some discordant results analyzed to understand the causes. The study provided detailed figures on the sensitivity, specificity and predictive values of IHC in comparison to FISH, discussing the implications of these findings in clinical practice. This study underscores the significance of a complementary diagnostic strategy combining both IHC and FISH for the reliable determination of HER2 status in breast carcinoma. The findings advocate for an integrated approach to enhance accuracy, improve treatment decisions and ultimately, patient outcomes in breast cancer care.
How to cite this article:
Jasmeen Tabassum, Lubna Yasmeen and Idrees Akhter Afroze. Assessment of HER2 Amplification in Breast Carcinoma: A Cross‐Sectional Study Comparing IHC
and Fish.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.3.113.117
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.3.113.117